Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of this study is to determine if Eltrekibart alone is more effective than a placebo in helping patients achieve remission, which means a reduction or disappearance of symptoms. The study will involve adult patients who have moderately to severely active Ulcerative Colitis. Participants will receive either Eltrekibart alone, Mirikizumab alone, a combination of both, or a placebo. The study will last for several weeks, with the main goal being to see how many participants achieve remission by the end of the study period.

Throughout the study, participants will receive their treatments through injections or infusions, depending on the medication. The study will monitor the participants’ health and response to the treatment over time. The results will help determine the potential benefits of using these medications for treating Ulcerative Colitis and may provide new insights into managing this condition more effectively.

The purpose of the study is to compare the effectiveness, safety, and immune response of AVT16 and Entyvio in people aged 18 to 80 who have moderate to severe active ulcerative colitis. Participants will receive either AVT16 or Entyvio, and some may receive a placebo. The study will last for about 46 weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, participants will be assessed at various intervals to see how well the treatment is working. This includes checking for clinical responses, which are improvements in symptoms, and clinical remission, which is when symptoms are reduced or disappear. The study will also look at mucosal healing, which is the healing of the lining of the colon, and other health markers like albumin and CRP levels. Safety will be monitored by looking at any side effects or reactions to the infusion. The goal is to determine if AVT16 is as effective and safe as Entyvio for treating ulcerative colitis.

The purpose of this research is to determine how well oral tebipenem pivoxil works compared to intravenous imipenem-cilastatin in treating these urinary tract infections. The study will measure whether the infections are cured and if the bacteria causing the infections are eliminated. The medications will be given to adult patients who are in the hospital.

During the study, patients will receive treatment for up to 10 days. The study team will monitor patients’ symptoms and take urine samples to check if the infection is responding to treatment. They will also check for any side effects from the medications. After the treatment period ends, patients will have follow-up visits to ensure the infection has been properly treated.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

The purpose of the study is to evaluate how well these medications work in treating moderate or severe diabetic foot infections. Participants will be randomly assigned to receive either the new medications, Contezolid Acefosamil and Contezolid, or the existing medication, Linezolid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for a period of up to 28 days, during which the participants’ health and response to the treatment will be closely monitored by the study team.

Throughout the study, the safety and tolerability of the medications will be assessed, meaning the researchers will check for any side effects or adverse reactions. The main goal is to see if the new medications are as effective or more effective than Linezolid in treating the infections. Participants will have regular check-ups and assessments to track their progress and the effectiveness of the treatment. The study aims to provide valuable information that could lead to improved treatment options for people with diabetic foot infections.

The purpose of the study is to determine if milvexian can effectively lower the risk of major adverse cardiovascular events, such as heart attacks, strokes, or cardiovascular-related deaths, when added to the usual care. Participants in the study will be randomly assigned to receive either milvexian or a placebo, and they will continue their regular heart medications. The study will last for a period of up to 48 weeks, during which participants will take the study medication orally in the form of film-coated tablets.

Throughout the study, participants will be monitored for any heart-related events and overall health. The goal is to see if milvexian can provide additional protection against serious heart problems compared to the placebo. This research aims to improve the understanding of how to better prevent recurrent cardiovascular events in patients who have recently suffered from a heart attack.

The purpose of the study is to determine if Inclisiran can reduce the risk of serious heart problems, such as heart attacks, strokes, or the need for urgent procedures to restore blood flow to the heart. The study will be conducted over a period of time, during which participants will receive regular injections of the medication or placebo and will be monitored for any heart-related events. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Participants will be closely observed throughout the study to track the time it takes for any major heart events to occur. The study will also look at other outcomes, such as the time to cardiovascular death and overall mortality. The goal is to gather information on the safety and effectiveness of Inclisiran in preventing heart-related issues in people who are at high risk but have not yet had a major cardiovascular event.

Participants in the study will be randomly assigned to receive either Selatogrel or a Selatogrel matching placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow participants over a period to observe the occurrence of death or another heart attack after they have self-administered the treatment.

The study will also monitor for any safety concerns, such as bleeding events, that may occur within two days after taking the treatment. Additionally, researchers will look at other outcomes like hospital visits for heart failure within 30 days after treatment. This trial aims to provide valuable information on the potential benefits and risks of using Selatogrel for individuals at risk of having another heart attack.

Participants in the study will receive either Obicetrapib or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The study will last for a period of time, during which participants will take the medication or placebo and attend regular check-ups to monitor their health and any changes in their condition.

The goal of the study is to gather information on how Obicetrapib affects the risk of serious cardiovascular events in people with ASCVD. By participating, researchers hope to better understand the potential benefits of this medication for those who are not adequately helped by their current treatments. The study will provide valuable insights into the effectiveness of Obicetrapib in managing heart and blood vessel health in individuals with this condition.